January 29, 2013

Genzyme and Isis Announce FDA Approval of KYNAMROTM (mipomersen sodium) Injection for the Treatment of Homozygous Familial Hypercholesterolemia

 

Genzyme and Isis Announce FDA Approval of KYNAMROTM (mipomersen sodium) Injection for the Treatment of Homozygous Familial Hypercholesterolemia

Paris, France and Carlsbad, California, January 29, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme, and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for KYNAMROTM (mipomersen sodium) injection. KYNAMRO, given as a 200 mg weekly subcutaneous injection, has been approved as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (Apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).